# OLP-1002 is Being Studied in the Treatment of Pain.

> **NCT03760913** · EARLY_PHASE1 · COMPLETED · sponsor: **OliPass Corporation** · enrollment: 116 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** OLP-1002 (Test): Part A, Single Ascending Dose
- **DRUG:** OLP-1002 (Test): Part B, Multiple Ascending Dose
- **OTHER:** Placebo: Placebo Part A, Single Ascending Dose
- **OTHER:** Placebo: Placebo Part B, Multiple Ascending Dose

## Key facts

- **NCT ID:** NCT03760913
- **Lead sponsor:** OliPass Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-21
- **Primary completion:** 2020-10-16
- **Final completion:** 2020-10-16
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2021-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760913, "OLP-1002 is Being Studied in the Treatment of Pain.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03760913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*